Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is GBX 2,018.75 ($25.51).
Separately, Berenberg Bank increased their price target on shares of Hikma Pharmaceuticals from GBX 1,960 ($24.77) to GBX 2,000 ($25.27) and gave the stock a “hold” rating in a research note on Monday, February 26th.
Get Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Price Performance
Hikma Pharmaceuticals Increases Dividend
The firm also recently announced a dividend, which will be paid on Friday, May 3rd. Shareholders of record on Thursday, March 21st will be given a dividend of $0.47 per share. This represents a yield of 1.86%. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.25. The ex-dividend date is Thursday, March 21st. Hikma Pharmaceuticals’s dividend payout ratio is presently 8,507.46%.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded.
Read More
- Five stocks we like better than Hikma Pharmaceuticals
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Best Bear Market Funds: Top 3 Investment Options to Consider
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.